Evaluation of COVID-19 vaccination in healthcare professionals





COVID-19, Inactive vaccine, healthcare workers


Background: Vaccination is one of the most successful and cost-effective healthcare initiatives for preventing infectious diseases, and vaccines are of exceptional importance to control and prevent COVID-19.

Objectives: In our study, the results of the COVID-19 vaccine applications, which started in healthcare workers after determining the priority groups, were evaluated.

Design and Setting: The study population, which was planned as a retrospective cohort study, consists of healthcare professionals working in Kayseri city center.

Methods: 24.421 healthcare workers from file records were included in this study. This study consists of two independent phases. Only the retrospective registry was not scanned, and the demographic information, vaccination status, and source case information of the healthcare workers who were found positive were questioned by phone.

Results: The rates of PCR (+) healthcare workers in the pre-vaccination period were 5.96% and 2.53% in the post-vaccination period. Considering the vaccination status of all healthcare workers, 5.14% of the unvaccinated ones were found to be PCR (+), while 2.04% of those vaccinated were PCR (+) (p<0.001).

Conclusions: The infection protection rate of the inactivated vaccine administered to healthcare workers was found to be 52.86% in the field. In our study evaluating the inactive CoronaVac vaccine, it is seen that the vaccine will strengthen us in the fight against the epidemic and can be preferred among the current vaccine options in line with the data obtained.


Download data is not yet available.


Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. Journal of Autoimmunity. 2020;109:102434. PMID: 32143990; https://doi.org/10.1016/j.jaut.2020.102434.

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. New England Journal of Medicine. 2020;382(21):1969-1973. PMID: 32227757; https://doi.org/10.1056/NEJMp2005630.

Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616. PMID: 33159850; https://doi.org/10.1016/S0140-6736(20)32318-7.

Zimmer C, Corum J, Wee S-L. Coronavirus Vaccine Tracker. The New York Times. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. Accessed in 2021 (April 27).

CoronaVac COVID-19 Vaccine. Available from: https://www.precisionvaccinations.com/vaccines/coronavac-covid-19-vaccine. Accessed in 2021 (April 27).

Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases. 2021;21(1):39-51. PMID: 33069281; https://doi.org/10.1016/S1473-3099(20)30831-8.

Organization WH. DRAFT landscape of COVID-19 candidate vaccines. World Health Organization (2020). Available from: https://www.who.int/publications/m/item/draft-landscape-ofcovid-19-candidate-vaccine.

Palacios R, Patiño EG, de Oliveira Piorelli R, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853. PMID: 33059771; https://doi.org/10.1186/s13063-020-04775-4.

Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Published online 2021:3. PMID: 33849629; https://doi.org/10.1186/s13063-021-05180-1.

Palacios R, Batista A P, Albuquerque C S N, et al. "Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study." (2021). SSRN-id: 3822780.

M Bueno S, Abarca K, A González P, et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. :1-32. medRxiv 2021.03.31.21254494; https://doi.org/10.1101/2021.03.31.21254494.

Sinovac: Etkinlik oranını artırmak için iki doz arası süreyi uzatın. euronews. Available from: https://tr.euronews.com/2021/04/12/sinovac-tan-ac-klama-etkinlik-oran-n-art-rmak-icin-iki-doz-aras-sureyi-uzat-n. Accessed in 2021 (April 18).




How to Cite

Özsaydı, S., Aslaner, H. ., Simsek, E., & Benli, A. R. . (2023). Evaluation of COVID-19 vaccination in healthcare professionals. Chronicles of Precision Medical Researchers, 4(2), 179–184. https://doi.org/10.5281/zenodo.8201997